<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7076512\results\search\drugs\results.xml">
  <result pre="selective and effective antivirals, from which only acyclovir (ACV) and" exact="ganciclovir" post="(GCV) were incorporated into nanomaterials; a complete classification of"/>
  <result pre="used, either alone or in combination [57]. These include also" exact="amantadine" post="and neuraminidase inhibitors (zanamivir and oseltamivir), that have been"/>
  <result pre="against influenza virus infection [58,59,60]. Briefly, the antiviral mechanism of" exact="amantadine" post="is based on nterference with the viral protein, M2"/>
  <result pre="it is taken inside the cell by endocytosis [61]. Also," exact="oseltamivir" post="carboxylate mechanism implies a selective inhibition of influenza virus"/>
  <result pre="included/encapsulated/incorporated into nanomaterials. The representative nucleoside reverse transcriptase inhibitor (NRTI)" exact="zidovudine" post="(AZT) is phosphorylated intracellular by kinases specific to AZT"/>
  <result pre="41, 44, 67, 70, 210, 215, and 219 [72]. Also," exact="lamivudine" post="(LAM), another NRTI agent, enters cells by passive diffusion,"/>
  <result pre="by deoxycytidine monophosphate kinase and nucleoside diphosphate kinase to yield" exact="lamivudine" post="5′-triphosphate, which is the active anabolite [73]. Tenofovir disoproxil"/>
  <result pre="the active anabolite [73]. Tenofovir disoproxil is a derivative of" exact="adenosine" post="5′-monophosphate lacking a complete ribose ring, and it is"/>
  <result pre="active against HIV-1, HIV-2 and HBV. After a rapid hydrolysis," exact="tenofovir" post="is formed, being then phosphorylated by cellular kinases to"/>
  <result pre="being then phosphorylated by cellular kinases to its active metabolite," exact="tenofovir" post="diphosphate which is a competitive inhibitor of viral reverse"/>
  <result pre="infectious form [77,78]. Only SQV, indinavir, ATV, RTV, NFV and" exact="lopinavir" post="are currently employed in nanotechnology research. There are two"/>
  <result pre="HSV treatment in this case for the topical form of" exact="trifluridine" post="(TFT) and ganciclovir (ACV analog) gels, is denoted by"/>
  <result pre="this case for the topical form of trifluridine (TFT) and" exact="ganciclovir" post="(ACV analog) gels, is denoted by low retention time"/>
  <result pre="on the membrane [113]; transferrin-conjugated quantum rod nanoparticles conjugated with" exact="saquinavir" post="crossed an in vitro BBB model by exploiting a"/>
  <result pre="with PMA amphiphilic polymer and functionalized with the antiretroviral peptide" exact="enfuvirtide" post="crossed the BBB by a passive diffusion, probably mediated"/>
  <result pre="this drawback. Patel et al. [156] obtained nanosuspensions—NS based on" exact="povidone" post="polymer- polyvinylpyrrolidone (PVP) K30, poloxamers steric stabilizer (188 and"/>
  <result pre="and RTV and also LNPs containing ATV + RTV +" exact="tenofovir" post="(TFV—an HIV NRTIs), the last ones being prepared in"/>
  <result pre="RNA; ssDNA: single stranded DNA; ssRNA: single stranded RNA; TAF:" exact="tenofovir" post="alafenamide; TEM: transmission electron microscopy; Tf: transferrin; TFV: tenofovir;"/>
  <result pre="foscarnet therapy remodels thymidine analogue mutations and alters resistance to" exact="zidovudine" post="and lamivudine in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral"/>
  <result pre="remodels thymidine analogue mutations and alters resistance to zidovudine and" exact="lamivudine" post="in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral for herpes"/>
  <result pre="A (H5N1) InfectionN. Engl. J. Med.20053532667267210.1056/NEJMoa05451216371632 64.TeH.S.RandallG.JensenD.M.Mechanism of action of" exact="ribavirin" post="in the treatment of chronic hepatitis CGastroenterol. Hepatol.20073218225 65.Kre�?merováM.Amino"/>
  <result pre="DNA Virus and Retrovirus InfectionsClin. Microbiol. Rev.20031656959610.1128/CMR.16.4.569-596.200314557287 67.LeeH.W.ParkJ.Y.AhnS.H.An evaluation of" exact="entecavir" post="for the treatment of chronic hepatitis B infection in"/>
  <result pre="112.KuoY.-C.ChenH.-H.Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of" exact="zidovudine" post="and lamivudine across the in vitro blood–brain barrierInt. J."/>
  <result pre="nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of zidovudine and" exact="lamivudine" post="across the in vitro blood–brain barrierInt. J. Pharm.200632716016910.1016/j.ijpharm.2006.07.04416939704 113.MishraV.MahorS.RawatA.GuptaP.N.DubeyP.KhatriK.VyasS.P.Targeted"/>
  <result pre="HIV reservoirsEur. J. Pharm. Biopharm.2019138486310.1016/j.ejpb.2018.06.00229879528 125.ShenY.TuJ.Preparation and ocular pharmacokinetics of" exact="ganciclovir" post="liposomesAAPS J.20079E37110.1208/aapsj090304418170984 126.FengM.CaiQ.ShiX.HuangH.ZhouP.GuoX.Recombinant high-density lipoprotein complex as a targeting"/>
  <result pre="therapy significantly enhanced by targeted liposome deliveryAIDS2008221961196910.1097/QAD.0b013e32830efd9618753929 131.GagnéJ.-F.DésormeauxA.PerronS.TremblayM.J.BergeronM.G.Targeted delivery of" exact="indinavir" post="to HIV-1 primary reservoirs with immunoliposomesBBA Biomembr.2002155819821010.1016/S0005-2736(01)00432-1 132.ClaytonR.OhagenA.NicolF.Del VecchioA.M.JonckersT.H.M.GoethalsO.Van"/>
  <result pre="of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with" exact="amantadine" post="through ROS-mediated AKT signaling pathwaysIJN2018132005201610.2147/IJN.S15599429662313 136.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity of selenium"/>
  <result pre="AKT signaling pathwaysIJN2018132005201610.2147/IJN.S15599429662313 136.LiY.LinZ.GuoM.XiaY.ZhaoM.WangC.XuT.ChenT.ZhuB.Inhibitory activity of selenium nanoparticles functionalized with" exact="oseltamivir" post="on H1N1 influenza virusIJN2017125733574310.2147/IJN.S14093928848350 137.LiY.LinZ.ZhaoM.GuoM.XuT.WangC.XiaH.ZhuB.Reversal of H1N1 influenza virus-induced"/>
  <result pre="Administration in RatsPLoS ONE201510e014039910.1371/journal.pone.014039926461917 141.KirimlioğluG.Y.ÖztürkA.A.Preparation and in vitro characterization of" exact="lamivudine" post="loaded nanoparticles prepared by acid and/or ester terminated PLGA"/>
  <result pre="inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyNanomedicine20161210912210.1016/j.nano.2015.09.00926472049 148.SavageA.C.TathamL.M.SiccardiM.ScottT.VourvahisM.ClarkA.RannardS.P.OwenA.Improving" exact="maraviroc" post="oral bioavailability by formation of solid drug nanoparticlesEur. J."/>
  <result pre="Templating for the Topical Treatment of Herpesviruses InfectionsPharmaceutics2018104610.3390/pharmaceutics10020046 156.PatelG.V.PatelV.B.PathakA.RajputS.J.Nanosuspension of" exact="efavirenz" post="for improved oral bioavailability: Formulation optimization, in vitro, in"/>
  <result pre="HIV treatmentJ. Nanopart. Res.201315204010.1007/s11051-013-2040-4 180.ReddyP.P.ReddyB.M.PrakashJ.LathaK.PrashanthiD.Formulation and characterisation of chitosan based" exact="lamivudine" post="nanoparticlesEJPMR20144377383 181.SanchezC.G.MolinskiS.V.GongoraR.SosulskiM.FuselierT.MacKinnonS.S.MondalD.LaskyJ.A.The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy"/>
  <result pre="and DSC; EFV [146] - Folic acid-conjugated-P407 NPs based on" exact="folic acid" post="conjugated with P407 with inclusion of ATV and RTV"/>
 </snippets>
</snippetsTree>
